Patents by Inventor Denis Paul Harkin
Denis Paul Harkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11254986Abstract: An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.Type: GrantFiled: July 21, 2016Date of Patent: February 22, 2022Assignee: Almac Diagnostics Services LimitedInventors: Timothy Davison, Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard, Steven Walker, Laura Taggart, Eileen Parkes
-
Publication number: 20210254166Abstract: Methods for characterising and/or prognosing cancer in a subject comprise determining the expression level of at least one, and preferably 12, genes selected from Table 1 in a sample from the subject wherein the determined expression level is used to provide a characterisation of and/or a prognosis for the cancer. Determined expression levels are used to generate a signature score. The methods permit metastatic disease to be identified and monitored and guide therapeutic interventions.Type: ApplicationFiled: June 17, 2016Publication date: August 19, 2021Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Steven WALKER, Laura HILL, Andrena MCCAVIGAN, Sinead DONEGAN, Timothy DAVISON, Richard KENNEDY, Denis Paul HARKIN, Bethanie PRICE
-
Patent number: 11091809Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: December 3, 2013Date of Patent: August 17, 2021Assignee: Almac Diagnostic Services LimitedInventors: Denis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan
-
Publication number: 20190316203Abstract: An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.Type: ApplicationFiled: July 21, 2016Publication date: October 17, 2019Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Timothy Davison, Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard, Steven Walker, Laura Taggart, Eileen Parkes
-
Patent number: 10378066Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: February 7, 2017Date of Patent: August 13, 2019Assignee: Almac Diagnostic Services LimitedInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Patent number: 10280468Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.Type: GrantFiled: February 9, 2015Date of Patent: May 7, 2019Assignee: Almac Diagnostics LimitedInventors: Denis Paul Harkin, Richard Kennedy, Katherine E. Keating, Andrena McCavigan, Laura A. Hill, Steve Deharo, Timothy Davison, Fionnuala Patterson, Sinead Donegan, Gera Jellema, Charlie Gourley
-
Patent number: 10260097Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: June 4, 2012Date of Patent: April 16, 2019Assignee: Almac Diagnostics LimitedInventors: Denis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan
-
Patent number: 10214777Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: August 13, 2015Date of Patent: February 26, 2019Assignee: Almac Diagnostics LimitedInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Patent number: 10196691Abstract: A gene expression signature of colon cancer, microarrays including them and methods of using the colon gene expression signature are provided. The gene expression signature is especially useful for determining the prognosis of a patient diagnosed with colon cancer, such as stage II colon cancer. The gene signature described herein is also useful for determining effectiveness of surgical resection with or without adjuvant chemotherapy, and determining possibility of cancer recurrence in patients with colon cancer.Type: GrantFiled: January 25, 2012Date of Patent: February 5, 2019Assignee: ALMAC DIAGNOSTICS LIMITEDInventors: Denis Paul Harkin, Vitali Proutski, Julie Clarke, Peter Kerr, Richard Kennedy, Andreas Winter, Timothy Davison, Max Bylesjo, Vadim Farztdinov, Claire Trinder, Robert James Holt
-
Publication number: 20170198360Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: February 7, 2017Publication date: July 13, 2017Inventors: Jude O'DONNELL, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Patent number: 9677140Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: October 7, 2013Date of Patent: June 13, 2017Assignee: ALMAC DIAGONOSTICS LIMITEDInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Patent number: 9670547Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: September 15, 2011Date of Patent: June 6, 2017Assignee: ALMAC DIAGNOSTICS LIMITEDInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Publication number: 20170088902Abstract: The present invention relates to a cancer sub-type. Provided are methods for determining clinical prognosis of a subject with cancer, selecting whether to administer an anti-angiogenic therapeutic agent to a subject with cancer and predicting responsiveness of a subject with cancer to an anti-angiogenic therapeutic agent. The methods are based on assessing from the expression level of biomarkers disclosed herein whether the cancer belongs to the sub-type. Companion methods of treating cancer and agents for use in treating cancer are also provided.Type: ApplicationFiled: May 28, 2015Publication date: March 30, 2017Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Denis Paul HARKIN, Richard KENNEDY, Andrena MCCAVIGAN, Katherine KEATING, Laura HILL, Steve DEHARO, Timothy DAVISON, Fionnuala PATTERSON, Sinead DONEGAN, Gera JELLEMA, Charlie GOURLEY
-
Publication number: 20170073761Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.Type: ApplicationFiled: February 9, 2015Publication date: March 16, 2017Inventors: Denis Paul HARKIN, Richard KENNEDY, Katherine E. KEATING, Andrena MCCAVIGAN, Laura A. HILL, Steve DEHARO, Timothy DAVISON, Fionnuala PATTERSON, Sinead DONEGAN, Gera JELLEMA, Charlie GOURLEY
-
Publication number: 20160060705Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: August 13, 2015Publication date: March 3, 2016Applicant: Almac Diagnostics LimitedInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Publication number: 20140094379Abstract: A gene expression signature of colon cancer, microarrays including them and methods of using the colon gene expression signature are provided. The gene expression signature is especially useful for determining the prognosis of a patient diagnosed with colon cancer, such as stage II colon cancer. The gene signature described herein is also useful for determining effectiveness of surgical resection with or without adjuvant chemotherapy, and determining possibility of cancer recurrence in patients with colon cancer.Type: ApplicationFiled: January 25, 2012Publication date: April 3, 2014Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Denis Paul Harkin, Vitali Proutski, Julie Black, Peter Kerr, Richard Kennedy, Andreas Winter, Timothy Davison, Max Bylesjo, Vadim Farztdinov, Claire Wilson, Robert James Holt
-
Publication number: 20140031260Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: October 7, 2013Publication date: January 30, 2014Inventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Publication number: 20010051339Abstract: Analysis of the genes whose expression is affected by BRCA1 has identified a set of genes, each of which is up- or down-regulated by BRCA1. Each of these genes, alone or in groups, can be used to determine the mutational status of a BRCA1 gene, to determine whether a particular allelic variant affects BRCA1 function, to diagnose neoplasia, and to help identify candidate drugs which may be useful as anti-neoplastic agents.Type: ApplicationFiled: March 15, 2001Publication date: December 13, 2001Inventors: Jonathan Oliner, Fred Christians, Vivi Truong, Daniel Haber, James Bean, David Miklos, Denis Paul Harkin
-
Patent number: 6258536Abstract: Analysis of the genes whose expression is affected by BRCA1 has identified a set of genes, each of which is up- or down-regulated by BRCA1. Each of these genes, alone or in groups, can be used to determine the mutational status of a BRCA1 gene, to determine whether a particular allelic variant affects BRCA1 function, to diagnose neoplasia, and to help identify candidate drugs which may be useful as anti-neoplastic agents.Type: GrantFiled: December 1, 1998Date of Patent: July 10, 2001Inventors: Jonathan Oliner, Fred Christians, Vivi Truong, Daniel Haber, James Bean, David Miklos, Denis Paul Harkin